PP-6Q5-
TXR-3060

16 V

003060

TECHNICAL SUPPORT SECTION EFFICACY REVIEW - I

Disinfectants Branch

IN 6-5-81 OUT 6-12-81

Reviewed by James E. Wilson, Jr. Date 6/11/81

EPA Reg. No. or File Symbol 707-146

EPA Petition or EUP No.

Date Division Received 4/30/81

Type Product(s): I, (D), H, F, N, R, S

Data Accession No(s). 245181

Product Mgr. No. 31(Lee)

Product Name(s) Rohm and Haas DC - 100A

Company Name(s) Rohm and Haas Co.

Submission Purpose New Data

Chemical & Formulation Liquid

Active Ingredient(s):	%
Hyamine 3500 - 50%	10.0

1 of 2 ①

300.0 Introduction

Toxicology data, i.e. acute dermal study, was sent to the safety reviewer without the registration file. Therefore, no information can be given in this report as to the pattern or area of intended use or why only the dermal study is being submitted.

301.0 Data Summary

301.1 Brief Description of Study

Acute Dermal Toxicity in Rabbits. Report by Toxicology Department of Rohm and Haas Co., Spring House, PA 19477, dated April 30, 1979. (Accession No. 245181)

301.2 Study Summary

1. Method

Doses of 1.3, 2.0, 3.2 and 5.0 g/kg of the chemical were placed under an impervious cuff and allowed to remain in contact with the skin of rabbits for 24 hours. Each group contained six rabbits. Signs of toxicity were recorded for 14 days. All animals were subjected to an autopsy examination upon death or at termination of the study.

2. Results

Two rabbits died during the study, one each at 3.2 and 5.0 g/kg. Staining of the muzzle, scant tray droppings, apparent weight losses occurred in approximately 25% of the test animals. The skin was severely irritated by the chemical.

3. Conclusion

The dermal LD_{50} is greater than 5.0 g/kg.

302.0 Recommendations

The product, based on the data submitted, should be placed in Toxicity Category 3, for acute dermal toxicity.

It should be noted that the report does not indicate that the skin of the test animal was abraded as required in the proposed guidelines.

Formulation of this type generally are not highly toxic dermally. It is recommended that the study be accepted and the registrant be informed of the inadequacy.

304.0 CRP States

This product does not require special packaging based on the dermal toxicity.